Quarter Comparison
Revenue
Net Margin
EPS (Diluted)
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 exhibit99-1earningspressre.htm EX-99.1 Document Exhibit 99.1 MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position • Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsou
EX-99.1 2 exhibit99-1earningspressre.htm EX-99.1 Document Exhibit 99.1 MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position • Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline • Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4) • MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026 • MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter • Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028 ROCKVILLE, M D., August 13, 2026 (GLOBE NEWSWIRE) — MacroGen...
Source
Exhibit EX-99.1
0001125345-26-000054
Filed August 13, 2026 at 8:07 PM UTC. The figures above are from the audited statements, not from this release.